Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stallimycin (distamycin A) is a natural polypyrrole oligopeptide antibiotic originally isolated from *Streptomyces distallicus*. It is a well-characterized DNA minor groove binding agent with a high preference for AT-rich sequences (typically four to five base pairs). By binding non-covalently to the minor groove, it displaces water molecules and interferes with the binding of transcription factors and the activity of DNA-dependent enzymes, such as RNA and DNA polymerases. Historically developed by Farmitalia, it was marketed topically for the treatment of herpes simplex infections under the name stallimycin. However, due to systemic toxicity and the advent of more effective agents, its clinical use is now largely obsolete, and it is primarily employed as a research tool in molecular biology to study DNA-ligand interactions and as a template for designing sequence-specific DNA-binding drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on stallimycin.